HRP20170608T4 - Terapijske uporabe 1-[2-(2,4-dimetil-fenilsulfanil)fenil]piperazina - Google Patents
Terapijske uporabe 1-[2-(2,4-dimetil-fenilsulfanil)fenil]piperazina Download PDFInfo
- Publication number
- HRP20170608T4 HRP20170608T4 HRP20170608TT HRP20170608T HRP20170608T4 HR P20170608 T4 HRP20170608 T4 HR P20170608T4 HR P20170608T T HRP20170608T T HR P20170608TT HR P20170608 T HRP20170608 T HR P20170608T HR P20170608 T4 HRP20170608 T4 HR P20170608T4
- Authority
- HR
- Croatia
- Prior art keywords
- phenylsulfanyl
- piperazine
- dimethyl
- phenyl
- treatment
- Prior art date
Links
- YQNWZWMKLDQSAC-UHFFFAOYSA-N vortioxetine Chemical compound CC1=CC(C)=CC=C1SC1=CC=CC=C1N1CCNCC1 YQNWZWMKLDQSAC-UHFFFAOYSA-N 0.000 title claims 4
- 230000001225 therapeutic effect Effects 0.000 title 1
- 239000003814 drug Substances 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 4
- 238000011866 long-term treatment Methods 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 4
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000020401 Depressive disease Diseases 0.000 claims 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000004584 weight gain Effects 0.000 claims 2
- 235000019786 weight gain Nutrition 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37588510P | 2010-08-23 | 2010-08-23 | |
| DKPA201000739 | 2010-08-23 | ||
| EP11749331.2A EP2608789B2 (en) | 2010-08-23 | 2011-08-22 | Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine |
| PCT/DK2011/050317 WO2012025123A1 (en) | 2010-08-23 | 2011-08-22 | Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20170608T1 HRP20170608T1 (hr) | 2017-07-28 |
| HRP20170608T4 true HRP20170608T4 (hr) | 2024-12-06 |
Family
ID=44532506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170608TT HRP20170608T4 (hr) | 2010-08-23 | 2011-08-22 | Terapijske uporabe 1-[2-(2,4-dimetil-fenilsulfanil)fenil]piperazina |
Country Status (32)
| Country | Link |
|---|---|
| US (5) | US20130184291A1 (https=) |
| EP (1) | EP2608789B2 (https=) |
| JP (1) | JP5902169B2 (https=) |
| KR (1) | KR101816953B1 (https=) |
| CN (1) | CN103068389A (https=) |
| AP (1) | AP3583A (https=) |
| AR (1) | AR082501A1 (https=) |
| AU (1) | AU2011295465B8 (https=) |
| BR (2) | BR122020025600A2 (https=) |
| CA (1) | CA2807062C (https=) |
| CL (1) | CL2013000492A1 (https=) |
| CO (1) | CO6680652A2 (https=) |
| CY (1) | CY1118886T1 (https=) |
| DK (1) | DK2608789T4 (https=) |
| ES (1) | ES2625142T5 (https=) |
| FI (1) | FI2608789T4 (https=) |
| HR (1) | HRP20170608T4 (https=) |
| HU (1) | HUE034155T2 (https=) |
| IL (1) | IL224371A (https=) |
| LT (1) | LT2608789T (https=) |
| ME (1) | ME02674B (https=) |
| MX (1) | MX349724B (https=) |
| PL (1) | PL2608789T5 (https=) |
| PT (1) | PT2608789T (https=) |
| RS (1) | RS55851B2 (https=) |
| RU (1) | RU2564666C2 (https=) |
| SG (1) | SG187649A1 (https=) |
| SI (1) | SI2608789T2 (https=) |
| SM (1) | SMT201700239T1 (https=) |
| TW (1) | TW201212918A (https=) |
| WO (1) | WO2012025123A1 (https=) |
| ZA (1) | ZA201301385B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106103418A (zh) | 2014-01-31 | 2016-11-09 | 埃吉斯药物私人有限公司 | 沃替西汀盐的制备方法 |
| CN104119299B (zh) * | 2014-08-13 | 2016-08-17 | 北京蓝贝望生物医药科技股份有限公司 | 沃赛汀或沃替西汀的氢溴酸盐 |
| CN104119298B (zh) * | 2014-08-13 | 2016-08-24 | 北京蓝贝望生物医药科技股份有限公司 | 氢溴酸沃赛汀或氢溴酸沃替西汀 |
| CN104610195B (zh) * | 2015-01-30 | 2017-06-27 | 上虞京新药业有限公司 | 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途 |
| WO2018002115A1 (en) | 2016-07-01 | 2018-01-04 | H. Lundbeck A/S | Vortioxetine dosing regimes for fast onset of antidepressant effect |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8430581D0 (en) * | 1984-12-04 | 1985-01-09 | Ferrosan As | Treatment |
| DK0543584T3 (da) * | 1991-11-18 | 1996-07-01 | Lilly Industries Ltd | Benzo(b)thiophen-2-carboxamider til behandling af forstyrrelser i centralnervesystemet |
| US20080103179A1 (en) * | 2006-10-27 | 2008-05-01 | Tam Peter Y | Combination Therapy |
| EP2090769A1 (en) | 2000-10-02 | 2009-08-19 | Rohr, Inc. | Apparatus, method and system for gas turbine engine noise reduction |
| UA81749C2 (uk) * | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
| PL2044043T5 (pl) * | 2006-06-16 | 2022-05-02 | H. Lundbeck A/S | Bromowodorek 1-[2-(2,4-dimetylofenylosulfanylo)fenylo]piperazyny jako związek o połączonym działaniu wychwytu zwrotnego serotoniny i działaniu na 5-ht3 i 5-ht1a do leczenia upośledzenia funckji poznawczych |
| TW200848411A (en) | 2007-03-20 | 2008-12-16 | Lundbeck & Co As H | Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine |
| TW200932233A (en) * | 2007-11-13 | 2009-08-01 | Lundbeck & Co As H | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity |
-
2011
- 2011-08-17 TW TW100129338A patent/TW201212918A/zh unknown
- 2011-08-19 AR ARP110103029A patent/AR082501A1/es not_active Application Discontinuation
- 2011-08-22 SM SM20170239T patent/SMT201700239T1/it unknown
- 2011-08-22 ME MEP-2017-94A patent/ME02674B/me unknown
- 2011-08-22 EP EP11749331.2A patent/EP2608789B2/en active Active
- 2011-08-22 DK DK11749331.2T patent/DK2608789T4/da active
- 2011-08-22 AU AU2011295465A patent/AU2011295465B8/en active Active
- 2011-08-22 US US13/812,073 patent/US20130184291A1/en not_active Abandoned
- 2011-08-22 IL IL224371A patent/IL224371A/en active IP Right Grant
- 2011-08-22 JP JP2013525143A patent/JP5902169B2/ja active Active
- 2011-08-22 HU HUE11749331A patent/HUE034155T2/en unknown
- 2011-08-22 AP AP2013006768A patent/AP3583A/xx active
- 2011-08-22 LT LTEP11749331.2T patent/LT2608789T/lt unknown
- 2011-08-22 SG SG2013007380A patent/SG187649A1/en unknown
- 2011-08-22 RS RS20170404A patent/RS55851B2/sr unknown
- 2011-08-22 CN CN2011800406861A patent/CN103068389A/zh active Pending
- 2011-08-22 HR HRP20170608TT patent/HRP20170608T4/hr unknown
- 2011-08-22 CA CA2807062A patent/CA2807062C/en active Active
- 2011-08-22 WO PCT/DK2011/050317 patent/WO2012025123A1/en not_active Ceased
- 2011-08-22 MX MX2013001570A patent/MX349724B/es active IP Right Grant
- 2011-08-22 KR KR1020137004481A patent/KR101816953B1/ko active Active
- 2011-08-22 BR BR122020025600A patent/BR122020025600A2/pt not_active Application Discontinuation
- 2011-08-22 SI SI201131177T patent/SI2608789T2/sl unknown
- 2011-08-22 PL PL11749331.2T patent/PL2608789T5/pl unknown
- 2011-08-22 RU RU2013112890/15A patent/RU2564666C2/ru active
- 2011-08-22 ES ES11749331T patent/ES2625142T5/es active Active
- 2011-08-22 FI FIEP11749331.2T patent/FI2608789T4/fi active
- 2011-08-22 PT PT117493312T patent/PT2608789T/pt unknown
- 2011-08-22 BR BR112013002194A patent/BR112013002194A2/pt not_active Application Discontinuation
-
2013
- 2013-02-20 CL CL2013000492A patent/CL2013000492A1/es unknown
- 2013-02-21 CO CO13035030A patent/CO6680652A2/es unknown
- 2013-02-22 ZA ZA2013/01385A patent/ZA201301385B/en unknown
-
2017
- 2017-05-10 CY CY20171100501T patent/CY1118886T1/el unknown
-
2018
- 2018-09-07 US US16/124,497 patent/US20190000836A1/en not_active Abandoned
-
2020
- 2020-05-18 US US16/877,108 patent/US20210085674A1/en not_active Abandoned
-
2022
- 2022-01-07 US US17/570,998 patent/US20220370439A1/en not_active Abandoned
-
2023
- 2023-10-10 US US18/483,780 patent/US20240293397A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120144T4 (hr) | Terapijske uporabe spojeva koji imaju i sert i 5-ht3 i 5-ht1a aktivnost | |
| HRP20170608T4 (hr) | Terapijske uporabe 1-[2-(2,4-dimetil-fenilsulfanil)fenil]piperazina | |
| BR112013032122A2 (pt) | liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos | |
| CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
| JP2015057451A5 (https=) | ||
| HRP20241145T1 (hr) | Biciklički aza spojevi kao agonisti muskarinskih receptora | |
| MX2015005949A (es) | Nucleosidos que contienen aza-azucar antiviral. | |
| WO2013101897A3 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
| JP2015523407A5 (https=) | ||
| JP2010529118A5 (https=) | ||
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| IL232462A (en) | Annals of 2- (1, 2, 3-triazole-2-ram) benzamide and 3- (3,2,1-triazole-2-ram) picolinamide, containing and using pharmaceutical preparations | |
| JP2011524850A5 (https=) | ||
| BR112015029401A2 (pt) | derivados pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças | |
| HRP20171648T1 (hr) | Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze | |
| HRP20171908T1 (hr) | Farmaceutski pripravak koji sadrži ligande dopamin receptora i metode liječenja koje koriste ligande dopamin receptora | |
| MA37455A1 (fr) | Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique | |
| BR112014011981A8 (pt) | Formulações farmacêuticas sólidas orais, seus processos de preparação e usos | |
| JP2013516493A5 (https=) | ||
| IL230487B (en) | 6-(n-(7-chloro-1-hydroxy-3,1-dihydrobenzo[c][1,2]oxaborole-5-yl)methylsulfonamido)-5-cyclopropyl-2-(4-fluorophenyl)-n- Methylbenzofuran-3-carboxamide, their salts and pharmaceutical preparations containing them | |
| NZ700924A (en) | Dosage regimen for a pi-3 kinase inhibitor | |
| HRP20200662T1 (hr) | Ljekoviti pripravak koji sadrži spoj diamino heterocikličkog karboksamida kao aktivni sastojak | |
| HRP20171742T4 (hr) | 2,4,6-trifluor-n-[6-(1-metilpiperidin-4-karbonil)piridin-2-il]benzamid, namijenjen liječenju migrene oralnom ili intravenskom primjenom | |
| JO3587B1 (ar) | أشكال جرعات بينداموستين عن طريق الفم | |
| HRP20161389T1 (hr) | Derivati pantotenata namijenjeni liječenju neuroloških poremećaja |